source
- STAT+: Pharmalittle: We’re reading about a reticent FDA commish nominee, a Novo deal, and morePresident Trump’s nominee to lead the FDA was grilled by senators on hot button topics like China, vaccines, and abortion accessSTAT · 1mo ago↗ source
- Alnylam alumni lead RNAi biotech City Therapeutics to IPO filingBiotechs are rushing into the IPO queue. City Therapeutics submitted its public pitch late Thursday, the same night ADARx Pharmaceuticals priced its $446 million Nasdaq debut. Kendall Square-based ...Endpoints · 1mo ago↗ source
- Acadia misses mark in Alzheimer’s but concludes phase 3 ‘absolutely worth’ pursuingAcadia Pharmaceuticals’ phase 2 Alzheimer’s disease trial has missed its primary endpoint, but the company and analysts alike saw enough encouraging signals to support the continuation of a phase 3…